Skip to content
value.today

Hypha Labs, Inc.

FUNI
$2 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending September-2025
Net income
$-3 M
SEC filing
Employees
—

Hypha Labs, Inc. in brief

Hypha Labs, Inc. is a listed company in the Diagnostics and Research industry, based in Nevada, USA. Its last known market value was $2 M (January 2022); there is no current figure. Its shares trade under the symbol FUNI (OTC Markets Group).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
612.2%
Revenue growth
+8.0%
R&D / revenue
700.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue $3M, net income $-2M$3MFY18Fiscal year ending Sep 2019: revenue $3M, net income $-2M$3MFY19Fiscal year ending Sep 2020: revenue $3M, net income $-2M$3MFY20Fiscal year ending Sep 2021: revenue $3M, net income $-1M$3MFY21Fiscal year ending Sep 2022: revenue $3M, net income $-2M$3MFY22Fiscal year ending Sep 2023: revenue —, net income $0M—FY23Fiscal year ending Sep 2024: revenue —, net income $-1M—FY24Fiscal year ending Sep 2025: revenue —, net income $-3M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025——$-3M$-3M—
Sep 2024——$-2M$-1M—
Sep 2023——$-0M$0M—
Sep 2022$3M+8.0%$-1M$-2M-76.3%
Sep 2021$3M-2.7%$-1M$-1M-27.6%
Sep 2020$3M+0.8%$-2M$-2M-89.9%
Sep 2019$3M-10.2%$-2M$-2M-71.0%
Sep 2018$3M—$-2M$-2M-58.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-0M$0M$-0M$-0.02—
Sep 2024$-1M$0M$-1M$-0.01—
Sep 2023$0M——$0.00—
Sep 2022$-0M$0M$-0M$-0.03—
Sep 2021$-0M$0M$-0M$-0.01—
Sep 2020$-1M$0M$-1M$-0.04—
Sep 2019$-1M$0M$-1M$-0.04—
Sep 2018$-0M$0M$-0M$-0.04—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024 (from the annual report): revenue —, net income $-0M—Sep ’24Three months to Dec 2024: revenue —, net income $-1M—Dec ’24Three months to Mar 2025: revenue —, net income $-1M—Mar ’25Three months to Jun 2025: revenue —, net income $-1M—Jun ’25Three months to Sep 2025 (from the annual report): revenue —, net income $-1M—Sep ’25Three months to Dec 2025: revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue —, net income $-1M—Mar ’26Three months to Jun 2026: revenue —, net income $-0M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

Annual results

Revenue
—
Operating income
$-3 M
Net income
$-3 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$0 M
Total liabilities
$3 M
Total equity
$-2 M

As of September-2025

Markets and events: Hypha Labs, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-10 reverse split

Hypha Labs, Inc. scorecard#

Passes 0 of the 7 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
  • Growth0 of 2
  • Profitability0 of 2
  • Financial health0 of 2
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Hypha Labs, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Hypha Labs, Inc.: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Revenue———2,7002,5042,5742,5532,8401,898819
Cost of revenue———1,6341,7891,7791,7132,070904380
Gross profit———1,066715796840770994439
General and administrative1,417944103496r9341,4831,6742,057r1,2581,261r
Operating expenses3,0011,8274371,150r1,4882,9882,6832,5292,291r3,321
Operating income−3,001−1,827−437−1,150r−772−2,192−1,843−1,759−1,297r−2,882
Interest expense and finance costs106202364245r14514866———
Net interest income———630.9r—————
Other non-operating income (expense)−100471−244−1,027r86−11738105232r−817
Income before tax−3,102−1,356−682———————
Income tax—14————————
Income from continuing operations−3,102−1,371−682−2,178——————
Income from discontinued operations—585928120——————
Minority interests' share of net income—————————3,699
Net income attributable to shareholders−3,102−785247−2,057−687−2,309−1,805−1,654−1,065−3,699
Earnings per share, basic-0.02-0.010.00-0.03-0.01-0.04-0.04-0.04-0.04-0.20
Earnings per share, diluted-0.02-0.010.00-0.03-0.01-0.04-0.04-0.04-0.04-0.20
Shares, weighted average (basic)135101847466—————
Shares, weighted average (diluted)1351018474665346392918
Balance sheet
Cash and cash equivalents38912715629683324176178135
Receivables———33521524217916826798
Other current assets272898.613r60r5.57573——
Current assets321410766562827397629442544298
Property, plant and equipment6327—55r6478857279571,0271,140
Right-of-use (leased) assets2657—317414506————
Goodwill—————593————
Non-current assets89846447781,0611,391————
Total assets4094941,4091,3401,8881,7881,3561,3991,5711,447
Accounts payable47386122201r371388137326122158
Current liabilities1,119r1,3943,1222,9542,014773471385164212
Lease liabilities (non-current)—27—230330424————
Non-current liabilities—271597959272,105459———
Total liabilities2,5121,4203,2813,7492,9412,878930385164212
Retained earnings−23,649−20,547−19,762−20,009−17,952−17,265−14,956−13,150−11,497−10,432
Shareholders' equity−2,437−1,260−2,205−2,743−1,053−1,0894261,0151,4071,235
Total equity————————1,4071,235
Total liabilities and equity4094941,4091,3401,8881,7881,3561,3991,5711,447
Shares outstanding1471238775715848423522
Cash-flow statement
Depreciation and amortization———204292323261277254245
Share-based compensation1,85073459566404212334453246295
Cash from operating activities−380−1,034113−185−136−672−1,042−163−377−734
Capital expenditure−33−28—−18−56−141−45−207−141−14
Cash from investing activities−332,146263−660−286−341−135−207−141−72
Shares issued76——562057625369561460
Cash from financing activities360−1,292−1616056357721,325369561460
Change in cash−53−180215−240213−241148−2.243−346
Report10-K10-K10-K10-K/A10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Jun 30, 2026

Acquisitions and funding#

1 acquisitions

Businesses it acquired

Acquisitions by Hypha Labs, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
VSSL Enterprises LtdMar 2020Mar 2020——Annual report

Private share sales · funding history

Private share sales of Hypha Labs, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2014$2 MPrivate placement after listing$2 to $10 million31equitySEC
Apr 2014$6 MPrivate placement after listing$2 to $10 million17equitySEC

How Hypha Labs, Inc. compares in Diagnostics and Research

  • Revenue growth8.0% · higher than 58% of 90

Peer comparison · Diagnostics and Research

CompanyMarket capP/ENet marginRev. growth
Hypha Labs, Inc.🇺🇸$2 M——+8.0%
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%
Danaher Corporation🇺🇸$166.7 B38.5×16.9%+2.9%
WuXi AppTec Co., Ltd.🇨🇳$70.4 B25.4×42.1%—
Natera, Inc.🇺🇸$58.7 B—-5.7%+35.9%
Siemens Healthineers AG🇩🇪$52.8 B22.9×8.7%—
Lonza Group AG🇨🇭$51.9 B—-4.2%—
Agilent Technologies, Inc.🇺🇸$48.8 B33.9×19.5%+6.7%
IQVIA Holdings Inc.🇺🇸$45.1 B32.4×8.1%+5.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Hypha Labs, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Hypha Labs, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Hypha Labs, Inc.? Suggest a correction